First Xarelto trial set for April; blood thinner linked to severe bleeding risk

posted on:
February 24, 2017

Joseph VanZandt

The first of four bellwether trials for the Xarelto multidistrict litigation (MDL) is set to begin on April 24, 2017, in the Eastern District of Louisiana. This trial was initially scheduled for February, but Righting Injustice reports U.S. District Judge Eldon Fallon and all parties agreed to push the trial back to March, due in part to New Orleans hosting the National Basketball Association (NBA) All Star Game during the same period. Ongoing discovery then resulted in the trial being rescheduled for April 24, 2017.

More than 15,680 U.S. lawsuits have been filed against the German drug manufacturer Bayer AG and Johnson & Johnson’s Janssen Pharmaceuticals, which sells the drug in the U.S. The Jere Beasley Report recently noted that 14,000 of those lawsuits are pending through the MDL in New Orleans.

Louisiana native Joseph Boudreaux’s case will be the first MDL trial and the first Xarelto trial in the nation. Mr. Boudreaux filed suit in December 2014 after using Xarelto for less than a month and suffering a severe gastrointestinal bleed that landed him in the hospital and forced him to endure several blood transfusions.

The U.S. Food and Drug Administration (FDA) first approved Xarelto in July 2011 to prevent blood clots following orthopedic surgery and to prevent strokes for patients with atrial fibrillation. In 2012, Xarelto was approved to treat deep vein thrombosis and pulmonary embolism.

Less than three years after Xarelto’s initial approval, the FDA issued black box warnings because of the Xarelto’s significant risk of severe, uncontrolled internal bleeding, which occurs most frequently in patients’ gastrointestinal tracts and brains. Unlike its predecessor warfarin, Xarelto does not have an antidote to reverse the blood thinning process. Moreover, Plaintiffs allege that the Defendants have mislead doctors in the U.S. regarding the ability to measure Xarelto’s effect on patients’ blood through laboratory testing.

* * *

Lawyers in Beasley Allen’s Mass Torts Section are investigating injuries suffered by patients who took Xarelto. Injuries include gastrointestinal, rectal and brain bleeds, and deaths caused by major bleeding events. If you would like more information, contact Joseph VanZandt, a lawyer in the Mass Torts Section. You can reach him at 800-898-2034 or by email at

Jere Beasley Report, December 2016
Righting Injustice

Free Legal Consultation
At Beasley Allen, there is never a fee for legal services, unless we collect for you. Contact us today by filling out a brief questionnaire, or by calling our toll free number, 1-800-898-2034, for a free, no-cost no-obligation evaluation of your case.
back to top